DCs are critical for initiating immunity. The current paradigm in vaccine biology is that DCs migrating from peripheral tissue and classical lymphoid-resident DCs (cDCs) cooperate in the draining LNs to initiate priming and proliferation of T cells. Here, we observe subcutaneous immunity is Fms-like tyrosine kinase 3 ligand (Flt3L) dependent. Flt3L is rapidly secreted after immunization; Flt3 deletion reduces T cell responses by 50%. Flt3L enhances global T cell and humoral immunity as well as both the numbers and antigen capture capacity of migratory DCs (migDCs) and LN-resident cDCs. Surprisingly, however, we find immunity is controlled by cDCs and actively tempered in vivo by migDCs. Deletion of Langerin+ DC or blockade of DC migration i...
AbstractThe signals that control decisions of progenitor commitment involve the interplay of both cy...
Langerhans cells (LCs) are professional antigen presenting cells (APCs) residing in the epidermis. D...
Generating responses to tumor antigens poses a challenge for immunotherapy. This phase II trial (NCT...
DCs are critical for initiating immunity. The current paradigm in vaccine biology is that DCs migrat...
Skin-derived dendritic cells (DCs) are potent antigen-presenting cells with critical roles in both a...
Skin-derived dendritic cells (DC) are potent antigen presenting cells with critical roles in both ad...
Antigen-pulsed dendritic cells (DCs) are used as natural adjuvants for vaccination, but the factors ...
AbstractIn this study, we have taken advantage of the unique property of a potent dendritic cell (DC...
Human vaccines are delivered through skin, com-monly by the s.c. route, allowing access to a rich ne...
Antigen-presenting cells in the disease-free brain have been identified primarily by expression of a...
Harnessing DCs for immunotherapies in vivo requires the elucidation of the physiological role of dis...
Dendritic cells (DCs) are the antigen presenting cells that initiate and regulate immunity. By study...
International audienceFms-like tyrosine kinase 3 ligand (FLT3L) plays a major role in dendritic cell...
SummaryDendritic cells (DCs) comprise distinct functional subsets including CD8− and CD8+ classical ...
Generating responses to tumor antigens poses a challenge for immunotherapy. This phase II trial (NCT...
AbstractThe signals that control decisions of progenitor commitment involve the interplay of both cy...
Langerhans cells (LCs) are professional antigen presenting cells (APCs) residing in the epidermis. D...
Generating responses to tumor antigens poses a challenge for immunotherapy. This phase II trial (NCT...
DCs are critical for initiating immunity. The current paradigm in vaccine biology is that DCs migrat...
Skin-derived dendritic cells (DCs) are potent antigen-presenting cells with critical roles in both a...
Skin-derived dendritic cells (DC) are potent antigen presenting cells with critical roles in both ad...
Antigen-pulsed dendritic cells (DCs) are used as natural adjuvants for vaccination, but the factors ...
AbstractIn this study, we have taken advantage of the unique property of a potent dendritic cell (DC...
Human vaccines are delivered through skin, com-monly by the s.c. route, allowing access to a rich ne...
Antigen-presenting cells in the disease-free brain have been identified primarily by expression of a...
Harnessing DCs for immunotherapies in vivo requires the elucidation of the physiological role of dis...
Dendritic cells (DCs) are the antigen presenting cells that initiate and regulate immunity. By study...
International audienceFms-like tyrosine kinase 3 ligand (FLT3L) plays a major role in dendritic cell...
SummaryDendritic cells (DCs) comprise distinct functional subsets including CD8− and CD8+ classical ...
Generating responses to tumor antigens poses a challenge for immunotherapy. This phase II trial (NCT...
AbstractThe signals that control decisions of progenitor commitment involve the interplay of both cy...
Langerhans cells (LCs) are professional antigen presenting cells (APCs) residing in the epidermis. D...
Generating responses to tumor antigens poses a challenge for immunotherapy. This phase II trial (NCT...